Karyopharm Therapeutics (KPTI) Raw Materials (2019 - 2025)

Karyopharm Therapeutics has reported Raw Materials for 7 years, with the latest figure at $628000.0 in Q4 2025.

• For the quarter ending Q4 2025, Raw Materials fell 12.78% year-over-year to $628000.0; the trailing twelve-month figure through Dec 2025 stood at $628000.0 (down 12.78% YoY), and the FY2025 full-year result was $628000.0, down 12.78% from the prior year.
• Raw Materials for Q4 2025 stood at $628000.0, roughly flat from $630000.0 in the prior quarter.
• The five-year high for Raw Materials was $2.6 million in Q1 2022, with the low at $261000.0 in Q2 2022.
• Historically, Raw Materials has averaged $1.0 million across 5 years, with a median of $720000.0 in 2024.
• Annual changes were most pronounced in 2022 — Raw Materials tumbled 85.7% — and 2023, when it surged 330.65%.
• Karyopharm Therapeutics' Raw Materials stood at $1.8 million in 2021, then declined by 23.76% to $1.4 million in 2022, then tumbled by 59.64% to $553000.0 in 2023, then surged by 30.2% to $720000.0 in 2024, then slipped by 12.78% to $628000.0 in 2025.
• The last three Raw Materials figures came in at $628000.0 (Q4 2025), $630000.0 (Q3 2025), and $477000.0 (Q2 2025), per Business Quant data.